Something strange is happening.
If you have been in medicine long enough, you can feel it. Not in headlines. Not in studies. But in the rooms, in the conversations, and in the patients sitting across from you.
Over the past few years, something has shifted. Cancer feels different. It is not just the volume, although we are seeing more of it. It is the pattern. Younger patients. More aggressive presentations. People doing everything right and still ending up with diagnoses that do not quite make sense.
Once you start to notice that pattern, you cannot unsee it.
This is not a panic piece. It is not a conspiracy rant. It is a question. A simple one. What changed?
Something did. Whether that is environmental exposures, stress, immune dysregulation, post-viral effects, or something we do not fully understand yet, the reality is that clinicians are seeing it. And when enough people quietly notice the same thing, it is worth paying attention.
Around the same time these questions started coming up, another conversation began to emerge. Not in mainstream oncology, but just outside of it. A quieter conversation about something that does not fit the current model of cancer treatment.
Not targeted therapies. Not immunotherapy. Not the latest high-cost drug.
Something else entirely.
Old drugs. Cheap drugs. Drugs that have been around for decades. Drugs originally designed to treat something completely different, like parasites.
That is where things start to get interesting.
When people hear that, the immediate reaction is usually confusion. Are we saying cancer is caused by parasites? No. That is not what is being proposed.
What is being explored is something more biologically interesting. These drugs, ivermectin and mebendazole, are not just antiparasitic. They interact with cellular pathways that are directly involved in cancer biology. Energy production, cell division, inflammation, and immune signaling. The same systems that go wrong in cancer.
So the better question is not what antiparasitics have to do with cancer. The better question is what these drugs are doing inside the cell.
Cancer has one job, and that job is to grow. Relentlessly and aggressively, without the normal regulatory mechanisms that keep healthy cells in check. When you see something that appears to slow that process down, stop it, or even hold it in place, that matters.
In cancer, stability is not failure. Stability is control.
This brings us to a recent observational study that looked at patients with a wide variety of cancers who were given a combination of ivermectin and mebendazole. This was not a randomized controlled trial. It was not the gold standard. It was a prospective observational cohort, meaning patients were followed over time and outcomes were recorded.
This is not proof. No single study ever is. But it is a signal.
The study included just under 200 patients, with about 120 completing follow-up. These patients had different cancer types, stages, and treatment histories. This is real-world data. Messy, human, and complex.
The study evaluated something called the clinical benefit ratio. This includes complete response, partial response, and stable disease. Not just tumors shrinking, but tumors not growing.
In a disease that is defined by progression, that distinction matters.
Approximately 84 percent of patients fell into that clinical benefit category. That does not mean 84 percent were cured. It means that many patients either improved or remained stable, and a smaller percentage continued to worsen.
For anyone who has treated cancer patients, that is not insignificant.
This is a conversation that happens in clinic all the time. Patients look at their labs or circulating tumor cells and ask why things are not going down. But if they are not going up, that is often a win. Stability in a progressive disease represents control, and control can change outcomes.
Does this study prove that these medications are responsible for those outcomes? No. There are too many variables. Many patients were also undergoing chemotherapy, radiation, or surgery. This is not isolated data.
But it is enough to make you pause.
When you see a signal like this across multiple cancer types using inexpensive, widely available medications, it raises a reasonable question. Not whether this is a cure, but why it is not being studied more aggressively.
From a biological standpoint, the mechanisms are not as surprising as they might seem. Mebendazole disrupts microtubules, which are essential for cell division. Without microtubules, cells cannot divide. This is a mechanism shared with certain chemotherapy agents.
Mebendazole has also been shown to promote apoptosis, inhibit angiogenesis, and potentially target cancer stem cells. These stem cells are often responsible for recurrence and treatment resistance.
Ivermectin works differently. It affects multiple pathways at once, including cell proliferation, mitochondrial function, signaling pathways, and the tumor microenvironment. Rather than acting as a single-target drug, it behaves more like a multi-pathway disruptor.
Cancer is not a single-pathway disease. It adapts and finds alternate routes when one pathway is blocked. A multi-pathway approach may help reduce resistance.
When used together, these drugs may complement each other by targeting different aspects of cancer biology at the same time.
This is not magic. This is not a mystery cure. This is biology.
Naturally, this leads to another question. If something like this shows potential, why is it not being studied at a larger scale?
There are valid reasons for caution. The data is limited. The study is small. It is not randomized. More rigorous research is needed.
But large-scale clinical trials require funding, infrastructure, coordination, and time. Most of that research is driven by financial incentives. When a drug is off-patent, widely available, and inexpensive, the incentive to invest in large trials is different.
This is not about blame. It is about acknowledging how the system works.
Medicine does not move on possibility alone. It moves on evidence, infrastructure, and incentive. When those do not align, potential therapies can remain in a gray zone for years.
Not proven. Not disproven. Just not fully explored.
So where does that leave us?
Curious.
Not convinced. Not dismissive. Curious.
Because when a signal aligns with biologic plausibility, it is worth paying attention to.
At the end of the day, this is about patients. It is about outcomes. If something has the potential to slow progression, stabilize disease, or improve quality of life in a condition where progression is expected, it deserves careful and responsible exploration.
We do not have definitive answers. We do not have large-scale trials. What we have is a signal and a question that has not been fully answered.
And sometimes in medicine, those are the cases worth watching most closely.
Because today’s outlier can become tomorrow’s standard.
Or not.
But we will not know unless we ask the question and go looking for the answer.
If you are interested in exploring a more personalized, root-cause approach to your health, especially when things are not adding up the way they should, you can find us at Lindgren Functional Medicine. We would love to hear from you.
